Robert A. Copeland

10.3k total citations · 4 hit papers
66 papers, 5.0k citations indexed

About

Robert A. Copeland is a scholar working on Molecular Biology, Hematology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Robert A. Copeland has authored 66 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Molecular Biology, 7 papers in Hematology and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in Robert A. Copeland's work include Epigenetics and DNA Methylation (39 papers), Cancer-related gene regulation (38 papers) and RNA modifications and cancer (12 papers). Robert A. Copeland is often cited by papers focused on Epigenetics and DNA Methylation (39 papers), Cancer-related gene regulation (38 papers) and RNA modifications and cancer (12 papers). Robert A. Copeland collaborates with scholars based in United States, United Kingdom and Japan. Robert A. Copeland's co-authors include Victoria M. Richon, Margaret Porter Scott, Roy M. Pollock, Sarah K. Knutson, Kevin W. Kuntz, Mikel P. Moyer, Heike Keilhack, Richard Chesworth, Michael E. Solomon and Tim J. Wigle and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Robert A. Copeland

66 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

2013 581 citations Sarah K. Knutson, Natalie M. Warholic et al. Proceedings of the National Academy of Sciences profile →
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

2013 546 citations Scott R. Daigle, Edward J. Olhava et al. Blood profile →
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

2010 500 citations Christopher J. Sneeringer, Margaret Porter Scott et al. Proceedings of the National Academy of Sciences profile →
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

2018 451 citations Stephen J. Blakemore, Scott Ribich et al. profile →

Peers

Countries citing papers authored by Robert A. Copeland

Since Specialization

Citations

This map shows the geographic impact of Robert A. Copeland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Copeland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Copeland more than expected).

Fields of papers citing papers by Robert A. Copeland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A. Copeland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Copeland. The network helps show where Robert A. Copeland may publish in the future.

Co-authorship network of co-authors of Robert A. Copeland

This figure shows the co-authorship network connecting the top 25 collaborators of Robert A. Copeland. A scholar is included among the top collaborators of Robert A. Copeland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A. Copeland. Robert A. Copeland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	End-to-end SARS-CoV-2 transmission risks in sport: Current evidence and practical recommendations 2021 ·South African Journal of Sports Medicine ·Ben Jones, Gemma Phillips, (unknown), Thomas Edwards, Emily R. Adams, Lucia Bonadonna, Robert A. Copeland, (unknown), Caroline Dalton, Lisa Hodgson, Alfonso Jiménez, Simon Kemp, Jon Patricios, Vincenzo Romano Spica, Keith Stokes, Mike Weed, Clive Beggs	2
2	EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL 2017 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Allison E. Drew, Trupti Lingaraj, (unknown), Natalie M. Warholic, Igor Feldman, Christopher Plescia, J. Joshua Smith, Robert A. Copeland, Heike Keilhack, Elayne Chan-Penebre, Sarah K. Knutson, Scott Ribich, Alejandra Raimondi, Michael J. Thomenius	52
3	Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL -Rearranged Leukemia 2017 ·Molecular Cancer Therapeutics ·Carly Campbell, (unknown), David A. Drubin, Timothy M. Thomson, (unknown), (unknown), Nigel J. Waters, Edward J. Olhava, Roy M. Pollock, J. Joshua Smith, Robert A. Copeland, Stephen J. Blakemore, Kathrin M. Bernt, Scott R. Daigle	46
4	Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models 2017 ·Molecular Cancer Therapeutics ·Elayne Chan-Penebre, Kelli Armstrong, Allison E. Drew, Alexandra Grassian, Igor Feldman, Sarah K. Knutson, Kristy Kuplast‐Barr, Maria Roche, John Campbell, Peter Ho, Robert A. Copeland, Richard Chesworth, J. Joshua Smith, Heike Keilhack, Scott Ribich	127
5	The Elements of Translational Chemical Biology 2017 ·Cell chemical biology ·Robert A. Copeland, P. Ann Boriack‐Sjodin	12
6	A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening 2015 ·SLAS DISCOVERY ·Tim J. Wigle, Kerren K. Swinger, John E. Campbell, Michael D. Scholle, John Sherrill, (unknown), P. Ann Boriack‐Sjodin, Kevin W. Kuntz, Richard Chesworth, Mikel P. Moyer, Margaret Porter Scott, Robert A. Copeland	31
7	DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Christine R. Klaus, (unknown), Danielle Johnston, (unknown), J. Joshua Smith, Mikel P. Moyer, Robert A. Copeland, Edward J. Olhava, Margaret Porter Scott, Roy M. Pollock, Scott R. Daigle, Alejandra Raimondi	96
8	Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas 2014 ·PLoS ONE ·Sarah K. Knutson, Natalie M. Warholic, L. Danielle Johnston, Christine R. Klaus, Tim J. Wigle, (unknown), Bruce A. Littlefield, (unknown), J. Joshua Smith, Mikel P. Moyer, Robert A. Copeland, Roy M. Pollock, Kevin W. Kuntz, Alejandra Raimondi, Heike Keilhack	55
9	Small Molecule Control of Chromatin Remodeling 2014 ·Chemistry & Biology ·(unknown), Robert A. Copeland	44
10	Potent inhibition of DOT1L as treatment of MLL-fusion leukemia breakdown → 2013 ·Blood ·Scott R. Daigle, Edward J. Olhava, (unknown), Aravind Basavapathruni, Lei Jin, P. Ann Boriack‐Sjodin, Christina J. Allain, Christine R. Klaus, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Roy M. Pollock	546
11	A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients 2012 ·FEBS Letters ·Christina R. Majer, Lei Jin, Margaret Porter Scott, Sarah K. Knutson, Kevin W. Kuntz, Heike Keilhack, J. Joshua Smith, Mikel P. Moyer, Victoria M. Richon, Robert A. Copeland, Tim J. Wigle	116
12	Chemogenetic Analysis of Human Protein Methyltransferases 2011 ·Chemical Biology & Drug Design ·Victoria M. Richon, Danielle Johnston, Christopher J. Sneeringer, Lei Jin, Christina R. Majer, Keith Elliston, (unknown), Margaret Porter Scott, Robert A. Copeland	151
13	Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas breakdown → 2010 ·Proceedings of the National Academy of Sciences ·Christopher J. Sneeringer, Margaret Porter Scott, Kevin W. Kuntz, Sarah K. Knutson, Roy M. Pollock, Victoria M. Richon, Robert A. Copeland	500
14	Protein methyltransferases as a target class for drug discovery 2009 ·Nature Reviews Drug Discovery ·Robert A. Copeland, Michael E. Solomon, Victoria M. Richon	372
15	The Second Derivative Electronic Absorption Spectrum of Cytochrome c Oxidase in the Soret Region 1999 ·Biophysical Journal ·Martin P. Horvath, Robert A. Copeland, Marvin W. Makinen	7
16	Antiinflammatory 4,5-Diarylpyrroles. 2. Activity as a Function of Cyclooxygenase-2 Inhibition 1995 ·Journal of Medicinal Chemistry ·(unknown), Robert A. Copeland, M Covington, J M Trzaskos	103
17	Resonance Raman spectroscopy of the cytochrome c oxidase from Paracoccus denitrificans 1993 ·Biochemistry ·Stephen R. Lynch, (unknown), Robert A. Copeland	3
18	Long-distance cofactor interactions in terminal oxidases studied by second-derivative absorption spectroscopy 1993 ·Journal of Bioenergetics and Biomembranes ·Robert A. Copeland	7
19	Physicochemical characterization of bovine retinal arrestin 1991 ·Archives of Biochemistry and Biophysics ·(unknown), Patricia J. Hey, Raghavendra G. Mirmira, Robert A. Copeland	11
20	The structure of human acidic fibroblast growth factor and its interaction with heparin 1991 ·Archives of Biochemistry and Biophysics ·Robert A. Copeland, Hanlee P. Ji, (unknown), Robert W. Williams, Karen Thompson, Wayne K. Herber, Kenneth A. Thomas, Mark W. Bruner, James A. Ryan, (unknown), Gautam Sanyal, Robert D. Sitrin, Shigeko Yamazaki, C. Russell Middaugh	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact